DENVER, July 28, 2026--As artificial intelligence reshapes cybersecurity, risk management, and enterprise leadership, organizations are looking for practical strategies—not just predictions—to navigat
Merck (NYSE:MRK) reported that KEYTRUDA met its primary endpoint of progression free survival in the Phase 3 KEYNOTE C93 trial for advanced or recurrent endometrial cancer. The company highlighted thi
In July 2026, Aurobindo Pharma announced a royalty-free, non-exclusive licensing deal with Merck to supply generic alimatravir for HIV prevention across 129 low- and middle-income countries, while Mer
Scribe Therapeutics shares are up 30% since it raised $125 million in its initial public offering Friday. The cash will fund three clinical trials testing whether Scribe’s one-time treatments can ha
The drugmaker's rapid stock gains have led to a premium valuation, forcing investors to question its capacity for future growth.
Let's have a look at the top dow jones gainers and losers one hour before the close of the markets of today's session.
BMY heads into Q2 earnings with growth drugs driving momentum as legacy products decline, setting the stage for a closely watched earnings report.
Here is a way to get paid a significant income stream today from Eli Lilly stock, which you keep no matter what, while setting a price far below current levels where you would be willing to buy.
View interactive chart, options flow, and AI analysis for MRK on Zorveq Finance.
Open MRK Chart & Analysis →